Efficacy and Safety Outcomes with Diroximel Fumarate After Switching from Prior Therapies or Continuing on DRF: Results from the Phase 3 EVOLVE-MS-1 Study - Wray, S; Then Bergh, F; Wundes, A (Adv Ther, 2022)
et al.